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Histamine-releasing antibodies that act against the
epitope of the a chain of FceRI (anti-FceRIa anti-
body) that may affect pathogenesis in serum of
patients with chronic urticaria. We assessed the cap-
ability of anti-FceRIa antibody in sera from patients
with chronic urticaria to release histamine and cyto-
kines, and to induce the expression of endothelial
cell adhesion molecules. We also assessed the release
of in¯ammatory mediators from cultured foreskin
mast cells, and expression of endothelial cell adhe-
sion molecules on human dermal microvascular
endothelial cells. Cells were pretreated with mast
cell-conditioned media: culture media of mast cells
treated with sera from chronic urticaria patients con-
taining anti-FceRIa antibody. Histamine release
from human foreskin mast cells challenged with sera,
increased after both 20 min and 16 h intervals.
Leukotriene D4 release also increased at both 20 min
and 16 h. Tumor necrosis factor-a increased signi®c-
antly in foreskin mast cell culture challenged with
sera of chronic urticaria patients. After the stimula-
tion of human dermal microvascular endothelial cells
with the conditioned media, the expression of
intercellular cell adhesion molecule-1, vascular cell
adhesion molecule-1, and E-selectin increased sig-
ni®cantly. Treatment of the conditioned media with
anti-tumor necrosis factor-a monoclonal antibody
partially inhibited the expression of intercellular cell
adhesion molecule-1, vascular cell adhesion mole-
cule-1, and E-selectin. The data suggest that sera
from patients with chronic urticaria containing anti-
FceRIa antibody release mediators and tumor necro-
sis factor-a by activating human foreskin mast cells.
This release can play a pathogenic role in chronic
urticaria by activating endothelial cells, in part due
to the actions of tumor necrosis factor-a from mast
cells. Key words: anti-FceRIa antibody/cell adhesion
molecules/chronic urticaria/endothelial cells/mast cells. J
Invest Dermatol 118:658±663, 2002
U
rticaria is a common complaint that affects as much
as 2% of the population. It is often transient but can
be chronic, and there is no identi®able exogenous
allergen in most cases of chronic urticaria (CU;
Champion, 1990). Intradermal injection of auto-
logous serum elicits an immediate weal and ¯are response and mast
cell degranulation in the majority of patients with severe CU
(Grattan et al, 1986; 1990). Hide et al (1993) reported data that
implicate an autoimmune mechanism (anti-IgE antibody) as the
precipitating event in CU and Gruber et al (1988) noted that IgM
anti-IgE antibodies are found in cold urticaria, which suggests a
pathogenetic role for IgG.
More recent studies have suggested that there are autoantibodies
in the serum of patients with CU that mediate histamine release
from skin mast cells in vitro and in vivo (Grattan et al, 1991; Hide et al,
1993; Fiebiger et al, 1995; Niimi et al, 1996; Zweiman et al, 1996).
These results suggest that anti-FceRIa antibody is relevant to the
pathogenesis of severe CU (Sabroe and Greaves, 1997; Tong et al,
1997; Ferrer et al, 1998, 1999). Grattan et al (1991) ®rst described
histamine releasing autoantibodies in chronic idiopathic urticaria.
They suggested that histamine releasing autoantibodies are import-
ant in the pathogenesis of CU by stimulating or facilitating
degranulation of basophils and cutaneous mast cells through cross-
linking cell surface IgE receptors. Zweiman et al (1996) reported
that serum histamine releasing activity from patients with CU
appears in an IgG-containing fraction of the serum, which may
contain IgE in some cases. Tong et al (1997) noted that a large
fraction of patients with CU have antibodies directed to functional
FceRIa and suggested that CU may be autoimmune in origin. It
has also been reported that histamine release from mast cells in CU
is complement dependent (Ferrer et al, 1999).
Therefore, mast cells are considered to be the primary effector
cells in CU by releasing a variety of in¯ammatory mediators, such
as leukotriene, tryptase, prostaglandins, histamine, interleukin (IL)-
1, IL-6, IL-8, and tumor necrosis factor (TNF)-a (Walsh et al,
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1991; Bradding et al, 1992; Moller et al, 1993). Mast cells are
frequently found in close proximity to blood vessels. Release of
mast cell mediators can cause in¯ammation, as well as accumulation
and activation of other cells, including endothelial cells and
leukocytes.
The principal histologic ®nding in most cases of CU is dermal
edema. There is a variable cellular in®ltrate around vessels, in which
neutrophils and eosinophils predominate in the early lesion; in the
advanced lesion lymphocytes usually predominate and are accom-
panied by neutrophils and eosinophils (Jones et al, 1983;
Charlesworth et al, 1989; Frew and Kay, 1990; Thiers, 1996;
Sabroe et al, 1999). The migration of leukocytes from the blood
into the sites of tissue in¯ammation is an essential process;
in¯ammation with the adhesion of leukocytes to cell adhesion
molecules, such as the intercellular cell adhesion molecules-1
(ICAM-1), vascular cell adhesion molecules-1 (VCAM-1), and
E-selectin, which are regulated by various cytokines (Jones et al,
1983; Osborn et al, 1989; Stoolman, 1989; Springer, 1990; Shimizu
et al, 1991).
In this study, we puri®ed human foreskin mast cells and assessed
the capability of anti-FceRIa antibody in sera from patients with
CU to promote histamine and cytokine secretion, from the mast
cells. Puri®ed human foreskin mast cells were challenged and
cultured with sera that showed positivity to an anti-FceRIa
antibody detection test. Furthermore, we examined the effects of
sera of CU patients containing anti-FceRIa antibody and mast cell-
conditioned media pretreated with anti-FceRIa antibody, on the
expression of endothelial cell adhesion molecules by enzyme-linked
immunosorbent assay (ELISA).
MATERIALS AND METHODS
Subjects Sera were obtained from 21 normal, healthy volunteers (11
men and 10 women; mean age = 35; range = 20±52) and from 41
patients with CU (24 men and 17 women; mean age = 33; range = 22±
49). Weals in CU patients occurred at least twice a week, disappeared
within 24 h and lasted for more than 2 mo. Patients with clinical
evidence of urticarial vasculitis or physical urticaria, including cholinergic
urticaria, dermographism, and delayed pressure urticaria were excluded
from the study. The diagnosis for delayed pressure urticaria can be made
from carefully examining the patient's medical history and con®rmed
according to the method described by Barlow et al (1993). Anti-
histamine treatment was stopped at least 48 h and systemic
corticosteroids or immunosuppressive drugs at least 1 wk before serum
collection. Sera were collected and stored at ±70°C until used.
Production of human recombinant soluble FceRIa The gene
segment encoding the extracellular portion of human FceRIa was
provided by Dr M.H. Jouvin (Harvard Medical School, Boston, MA). In
order to generate the soluble form of human FceRIa, the gene encoding
the extracellular portion of human FceRIa was subcloned into pMT/
V5-His vector (pMT/V5-His-hFceRIa) under control of metallo-
thionein promoter (Invitrogen, San Diego, CA). The sequence of the
plasmid was con®rmed by automatic sequencing. A Drosophila Schneider
cell line stably expressing soluble human FceRIa was generated by
transfection with pMT/V5-His-hFceRIa together with pCoHYGRO
containing the Escherichia coli hygromycin B-phosphotransferase gene
under control of the Drosophila copia promoter (Invitrogen). Transfection
was performed according to standard CaPO4 protocols(Di Nocera and
Dawid, 1983), and transfected cells were selected with hygromycin
(300 mg per ml) for 6 wk. Expression was induced in cells by addition of
CaPO4 to the culture medium at a ®nal concentration of 500 mM for
36 h before use. The soluble FceRIa was obtained from the supernatants
of stable transfected insect cells.
ELISA for anti-FceRIa antibody Sera were screened for the
presence of anti-FceRIa antibody using ELISA. A volume of 50 ml of
2 mg soluble FceRIa per ml, diluted with carbonate buffer (pH 9.6), was
plated in 96-well ¯at-bottom plates and incubated overnight at 4°C. A
total of 100 ml of sera diluted 1 : 200 in Hank's balanced salt solution
with divalent cations (Irvine Scienti®c, Santa Ana, CA) and 1% bovine
serum albumin (Sigma, St Louis, MO) were added to each well and the
plates were incubated at 37°C for 1 h. After washing, 100 ml of
peroxidase-conjugated goat anti-human IgG (Sigma) or IgM (Sigma)
diluted 1:1000 by Hank's balanced salt solution with divalent cations and
5% newborn calf serum (GibcoBRL, Gathersberg, MD), was added to
each well and plates were incubated for 1 h. The plates were washed
again, and the binding of antibody was quanti®ed colorimetrically by the
addition of tetramethylbenzidine (1 mg per ml; Sigma). One milliliter of
a 100 mg per ml stock solution (tetramethylbenzidine in acetone) was
added to 100 ml of distilled water. Ten microliters of 30% H2O2 was
added immediately prior to use. The chromogenic reaction was stopped
with 25 ml 8 M H2SO4 and the plates were read spectrophotometrically
at 450 nm on an ELISA reader (Dynatech Laboratories, Alexandria, VA).
All were performed in triplicate.
Isolation of human newborn foreskin mast cells Samples of human
foreskin obtained from infants (1±5 d) were placed in RPMI-1640
medium immediately after surgical excision. Using a chopper, the skin
was ®nely diced into 3 mm fragments and subsequently washed with
Tyrod's buffer (pH 7.4) containing 137 nM NaCl, 0.36 nM NaH2PO4,
2.6 nM KCl, 1.0 nM CaCl2, 1.5 nM MgCl2, 119 nM NaHCO3,
5.5 nM glucose, and 1.0 g gelatin per l (TGCM buffer). The method
used for the digestion of skin fragments was modi®ed from that
described by Benyon et al (1986) in which chopped foreskin was added
to an enzyme buffer containing collagenase (0.25 mg per ml, type I),
hyaluronidase (0.08 mg per ml, type I), and DNase (0.16 mg per ml).
The tissue was incubated in enzyme buffer (1 g tissue per 10 ml) for 20,
20, and 30 min, respectively. The dispersed mast cells were harvested by
®ltration through nylon mesh and washed with erythrocyte-lysing buffer
(0.1 mol per l NH4Cl, 0.001 mol per l KH2CO3, and 2 3 10
±6 mol per
l ethylenediamine tetraacetic acid) and TGCM buffer. The dispersed
mast cells were separated using a rough Percoll gradient (density 1.0410),
quanti®ed, and assessed for purity by alcian and trypan blue staining. The
purity range of partially puri®ed mast cells was 25±60%.
Human dermal microvascular endothelial cells (HDMEC)
culture HDMEC were isolated from foreskins by trypsinization and
Percoll gradient centrifugation as described previously (Lee et al, 1992;
Swerlick et al, 1992a, 1992b). Cells were cultured in endothelial basal
media (Clonetics, San Diego, CA) with 5 ng epidermal growth factor
per ml (Clonetics), 1 mg hydrocortisone acetate per ml (Sigma), 5 3 10±
5 M dibutyryl cyclic adenosine monophosphate (Sigma), 100 U per ml
penicillin, 100 mg streptomycin per ml, 250 mg amphotericin B per ml
(Sigma), and 30% human serum (Irvine). The resulting cell culture was
free of contaminating ®broblasts as assessed by morphologic and
immunologic criteria. Experiments were conducted with HDMEC at
passages 2±6.
Mediator release and cytokine production from human foreskin
mast cells The partially puri®ed skin mast cells (2 3 105 cells) in
TGCM (1 ml) designated for mediator measurement were incubated
with the sera of CU patients (100 ml) at 37°C for 20 min, or 16 h, in a
CO2 incubator. Mast cells for cytokine production were incubated in a
CO2 incubator for 20 min, or 16 h, in both the presence and absence of
HDMEC. Reactions were terminated in an ice bath and samples were
centrifuged at 4°C. The supernatants were assayed for the presence of
histamine, leukotrienes, and cytokines. Because they decompose readily
in air, 0.1% gelatin (®nal concentration) was added to those supernatants
designated for measurement of leukotrienes.
Histamine assay Histamine was analyzed using the automated
¯uorometric method with a dialyzer (Astoria Analyzer Series 300,
Astoria-Paci®c International, Clackamas, ON) as described by Siraganian
(1974). The limit of detection of the assay was approximately 1±5 ng of
histamine per ml, and the amount of histamine released was expressed as
a percentage change of the total histamine present in the unstimulated
cells.
Leukotriene determination by radioimmunoassay The leukotriene
content in each of the cell supernatants was determined by
radioimmunoassay as described previously (Aharony et al, 1983). The
leukotriene antibody was diluted in buffered saline (5 mM MES, HEPES
adjusted to pH 7.4 with 1 M NaOH) containing 0.1% gelatin. Each
assay tube contained 100 ml of sample supernatant, antibody (50 ml of a
1:1000 dilution), and 50 ml of [3H]leukotriene D4 (LTD4; 2500±
3000 cpm) in buffered saline. Incubations were for 2 h at 4°C, and the
reaction was terminated by addition of 0.5 ml dextran-coated charcoal
(200 mg charcoal and 20 mg dextran mixed with 100 ml buffered
saline). Five minutes after incubation the mixture was centrifuged at
800 3 g and 4°C. A total of 0.4 ml of the supernatant was added to
Aquasol (NEN Life Science Products, Boston, MA) and counted using a
liquid scintillation spectrometer (Packard, model 3225). Standard curves
were constructed in the presence of antigen using LTD4. The detection
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limit of the assay was 0.045 pmol. LTD4 release was expressed as pmol
per 2 3 106 cells.
ELISA for detection of adhesion molecule expression HDMEC
were plated in 96-well ¯at-bottomed microtiter plates and allowed to
grow to con¯uence over 24 h at a concentration of 4 3 104 cells per
well. HDMEC were incubated with sera from anti-FceRIa antibody-
negative controls, anti-FceRIa antibody-negative CU patients, or anti-
FceRIa antibody-positive CU patients. A total of 100 ml of anti-ICAM-1
antibody (84H10, Immunotech Inc., Westbrook, ME), anti-VCAM-1
antibody (51±10C9, Pharmingen, San Diego, CA), or anti-E-selectin
antibody (1.2B6, Immunotech) was added to each well, and the plates
were then incubated at 37°C for 1 h. After washing, 100 ml of
peroxidase-conjugated goat anti-mouse IgG (Sigma), diluted 1:500, was
added to each well and the plates were incubated for an additional 1 h.
The plates were washed again, and the binding of antibody was quanti®ed
colorimetrically by the addition of tetramethylbenzidine (1 mg per ml;
Sigma). One millimeter of a 100 mg per ml stock solution (tetramethyl-
benzidine in acetone) was added to 100 ml of distilled water. Ten
microliters of 30% H2O2 was added immediately prior to use. The
chromogenic reaction was stopped with 25 ml 8 M H2SO4 and the plates
were read spectrophotometrically at 450 nm on an ELISA reader.
Controls included incubation with an irrelevant isotype-matched mouse
monoclonal antibody and omission of the primary antibody (blanks). The
results are expressed as optical density after subtraction of blank values.
Statistical analysis Mean values and SEM, were calculated for all
experiments. Data were analyzed using the Wilcoxon signed rank test or
repeated measures of analysis of variance. p-values of less than 0.05 were
considered signi®cant.
RESULTS
Detection of anti-FceRIa antibody, expression of adhesion
molecules on HDMEC, and isolation of human foreskin
mast cells When values were higher than the mean optical
density of the normal controls plus three times the standard
deviation, the optical density was considered reactive. Fourteen
(34%) of 41 sera samples from CU patients had reactivity to anti-
FceRIa antibody.
The expression of adhesion molecules on HDMEC after
stimulation with the anti-FceRIa antibody-positive sera of CU
patients is shown in Fig 1. The expression of ICAM-1, VCAM-1,
and E-selectin on HDMEC were not altered by pretreatment with
the anti-FceRIa antibody-positive sera of patients with CU at any
time during incubation (Fig 2). The culture of HDMEC with
unstimulated control, normal healthy control sera, and anti-FceRIa
antibody-negative sera also failed to express ICAM-1, VCAM-1,
and E-selectin; however, incubation with TNF-a used as positive
control, increased or induced the expression of ICAM-1,
VCAM-1, and E-selectin signi®cantly (Fig 1).
The number of human foreskin mast cells obtained by enzyme
digestion and rough Percoll gradient was 2 3 105 per g of tissue.
Purity ranged from 25% to 60% (Table I).
Effects of CU sera on mediator release, and production of
cytokines, in foreskin mast cells Spontaneous release of mast
cells (2 3 105) after 20 min, and 16 h incubation periods at 37°C
was 10.0 6 1.05% and 13.5 6 0.90%, respectively (Table I).
Human foreskin mast cells challenged by sera (100 ml) containing
anti-FceRIa antibody for periods of either 20 min or 16 h
increased histamine secretion markedly (25.3 6 1.72%, 45.7 6
2.68%) compared with the spontaneous rates of release (Table I).
Human foreskin mast cells challenged by 100 ml, 200 ml, or 300 ml
of anti-FceRIa antibody-positive sera for 20 min also showed
LTD4 release (1.09 6 0.07 pmol per 10
6 cells, 1.30 6 0.03 pmol
per 106 cells, and 1.08 6 0.02 pmol per 106 cells, respectively),
rather than spontaneous release (0.16 6 0.06 pmol per 106 cells).
LTD4 release for the 16 h treatment increased from 0.22 6 0.06 to
2.09 6 0.19 pmol per 106 cells (Table I). The amount of LTD4
released was very low compared with guinea pig lung mast cells
activated with the ovalbumin/anti-ovalbumin antibody reaction
(87.5 6 5.79 pmol per 106 cells). The amount of LTD4 released by
the high concentration (300 ml) in CU patients' sera was less than
released by the low concentration(100 ml) of CU patients' sera.
Human foreskin mast cells incubated with the sera of CU patients
for 16 h increased TNF-a production (376.7 6 67.45 pg per
2 3 105 cells), but did not increase IL-13, compared with
spontaneous release (203.6 6 24.93 pg per 2 3 105 cells;
Table I). TNF-a and IL-13 produced from foreskin mast cells
20 min after incubation were not detected by ELISA (data not
shown).
Human foreskin mast cells challenged with the sera (100 ml)
from anti-FceRIa-negative CU patients or normal sera for 20 min
or 16 h slightly increased histamine release, LTD4, and TNF-a
Figure 1. Regulation of the expression of endothelial adhesion
molecules by pretreatment with the sera of patients with CU.
After 16 h of incubation with normal control sera (NC), anti-FceRIa
antibody-negative sera of CU patients (NU), anti-FceRIa antibody-
positive sera of CU patients (PU), and TNF-a, the expression of
adhesion molecules was assessed by ELISA. Results are presented as
mean 6 SD. All data points were performed in triplicate. Results shown
are representative of those found in more than 10 separate experiments
and with nine different sera.
Figure 2. Time course of the induction of the expression of
endothelial adhesion molecules in response to anti-FceRIa
antibody-positive sera of CU patients. Following pretreatment with
the anti-FceRIa antibody-positive sera of CU patients, the expression of
endothelial adhesion molecules was assessed by ELISA. After 1, 4, 16,
and 24 h of incubation. Results are presented as mean 6 SD. Results are
presented as mean 6 SD. All data points were performed in triplicate.
Results shown are representative of three separate experiments and with
two different sera.
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production in mast cells, but this increase was not statistically
signi®cant, compared with the spontaneous rates of release
(Table I); however, one sample of anti-FceRIa antibody-negative
sera (100 ml; n = 4) remarkably increased the production of TNF-
a (329.8 pg per 2 3 105 cells). This value was similar to anti-
FceRIa antibody-positive sera.
Effects of CU sera on mediator release and the production
of cytokines in foreskin mast cells cocultured with
HDMEC When foreskin mast cells were cocultured with
HDMEC and stimulated with the anti-FceRIa antibody-positive
sera of CU patients for 16 h, the release of histamine
(39.3 6 3.79%), and production of LTD4 (1.98 6 0.74 pmol per
106 cells) and TNF-a (385.9 6 70.29 pg per 2 3 105 cells) did
not increase signi®cantly, compared with mast cells stimulated only
by patients' sera (45.7 6 2.68%, 2.09 6 0.19 pmol per 106 cells,
376.7 6 67.45 pg per 2 3 105 cells, respectively) (Table I).
Histamine release and LTD4 production were not increased in
the mast cells cocultured with HDMEC stimulated with anti-
FceRIa-positive sera of CU patients for 20 min compared with
mast cells stimulated only by patients' sera. The lack of production
of IL-13 from the mast cells challenged with the sera of CU patients
may be due to the small number of mast cells used.
The mast cells cocultured with HDMEC stimulated with the
anti-FceRIa-negative sera or normal sera did not signi®cantly
increase histamine release, LTD4, and TNF-a production (data not
shown).
Effects of cultured supernatants from anti-FceRIa antibody-
positive sera-treated mast cells on the expression of
adhesion molecules Direct transfer of culture supernatants
from anti-FceRIa antibody-positive sera-treated mast cells
(conditioned media) to HDMEC enhanced the expression of
ICAM-1, VCAM-1, and E-selectin after 4 h (Fig 3), but culture
supernatants from normal human sera or anti-FceRIa antibody-
negative sera did not affect expression (data not shown). After 16 h
of stimulation with media conditioned to HDMEC, enhanced
expression of ICAM-1 and VCAM-1 persisted, whereas E-selectin
expression returned to basal levels (Fig 4).
Effects of blocking antibodies to TNF-a on the expression
of adhesion molecules by conditioned media The potential
contribution of mast cell-generated TNF-a on the expression of
adhesion molecules was examined with blocking antibodies.
HDMEC were treated for 4±16 h with conditioned media in the
presence or absence of antibody, and the expression of adhesion
molecules was then measured. As shown in Fig 5, antibodies to
TNF-a inhibited enhanced ICAM-1, VCAM-1, and E-selectin
expression. This pattern of inhibition was reproduced in three
additional experiments. To know whether the anti-human IgG
antibody in some of the sera classi®ed as having a FceRI antibody
might induce the expression of endothelial cell adhesion molecules
directly and to determine whether coculture supernatants may have
synergistic effects for the expression of cell adhesion molecules, we
performed a coculture supernatant study. After the stimulation of
HDMEC with mixed culture supernatants of mast cells and
HDMEC stimulated with the anti-FceRIa antibody-positive sera
of CU patients, ICAM-1 and VCAM-1 expression were enhanced
at 4 h and 16 h. E-selectin expression was induced at 4 h, but at
not at 16 h; however, this expression on HDMEC did not increase
signi®cantly after pretreating with the mixed culture supernatants of
mast cells and endothelial cells treated with anti-FceRIa antibody-
positive sera of CU patients, compared with pretreatment of
conditioned media of mast cells treated with those sera.
Figure 3. Effect of conditioned medium from anti-FceRIa
antibody-positive sera-treated mast cells on the induction of the
expression of endothelial adhesion molecules. HDMEC were
treated with culture supernatant from culture media only (control), anti-
FceRIa antibody-positive sera-treated mast cells (mast cell), culture
supernatant from anti-FceRIa antibody-positive sera-treated mast cells-
endothelial cell coculture (coculture), and TNF-a for 4 h. The
expression of endothelial adhesion molecules was assessed by ELISA.
Results are presented as mean 6 SD. All data points were performed in
triplicate. Results shown are representative of six separate experiments
and with ®ve different sera. *p < 0.05 vs untreated HDMEC.




Histamine release (%) LTD4 (pmol per 10
6 cells) TNFa (pg per 2 3 105 cells) IL-13 (pg per 2 3 105 cells)
20 min 16 h 20 min 16 h 20 min 16 h 20 min and 16 h
Spontaneous 10.0 6 1.05 13.5 6 0.90 0.16 6 0.06 0.22 6 0.06 ND 203.6 6 24.93 ND
(+)Sera (100 ml)b 25.3 6 1.72** 45.7 6 2.68** 1.09 6 0.07** 2.09 6 0.19** ND 376.7 6 67.45** ND
EC + SM 9.6 6 1.39 11.7 6 1.84 NE 0.25 6 0.08 ND 202.8 6 29.80 ND
EC + SM + Sera 26.5 6 2.06** 39.3 6 3.79** 1.49 6 0.20** 1.98 6 0.74** ND 385.9 6 70.29** ND
(±)Sera (100 ml)c 13.8 6 2.74 16.0 6 2.38 NE 0.44 6 0.17 ND 244.4 6 29.14 ND
Normal sera (100 ml) 13.9 6 1.76 15.6 6 2.35 NE 0.21 6 0.09 ND 231.5 6 22.00 ND
aMast cells(2 3105 cells) from newborn foreskins were isolated using various enzymes (0.25 mg collagenase per ml, 0.08 mg hyaluronidase per ml, and 0.16 mg DNAse
per ml) using the Percoll gradient technique, and challenged with sera from CU patients for 20 min or 16 h. The values of EC alone did not detect in all kinds of experi-
ments.
bSera from anti-FceRIa-positive CU patients.
cSera from anti-FceRIa-negative CU patients. ND, no detection; EC, endothelial cells; SM, skin mast cells; NE, no experiment. Each value except TNF-a (n = 5), all
EC + SM, all (±) sera, and all normal sera (n = 4) represents the mean 6 SEM (n = 6).
**p < 0.001 compared with spontaneous release.
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DISCUSSION
The purity (25±60%) of human foreskin mast cells obtained using
the rough Percoll gradient method was higher than has been
reported for dispersed skin mast cells (8±25%; Benyon et al, 1986;
Table I); we observed by microscopy that the morphology of skin
mast cells had not changed (data not shown). The yield obtained
was similar to that of other workers (2 3 105 cells per g tissue), and
therefore, the Percoll gradient method would seem to be
satisfactory for the puri®cation of skin mast cells. The amount of
histamine released was higher than reported by other laboratories
(Benyon et al, 1986; Zweiman et al, 1996), and similar to that of
another report (Grattan et al, 1991). Although the amount of LTD4
released from skin mast cells activated with CU patients' sera was
very low, this release has not been reported previously.
It is well known that mast cells prepackage TNF-a in granules,
and store it for release (Walsh et al, 1991). TNF-a was detected in
mast cells stimulated with the sera of CU patients for 16 h. This
result suggests that TNF-a may be released immediately after
synthesis in preference to the release of preformed TNF-a.
Pretreatment of HDMEC in vitro with conditioned media led to
an increase in the expression of ICAM-1, VCAM-1, and E-
selectin, whereas this effect was not found with culture supernatants
of anti-FceRIa antibody-negative CU serum-treated mast cells,
CU serum with anti-FceRIa antibody only, or normal human
serum. These results suggest that this effect could be due to a
soluble mediator released by anti-FceRIa antibody-activated mast
cells.
The expression of ICAM-1 and VCAM-1 on HDMEC can be
increased by IL-1a or TNF-a. The onset of increase occurs at 4±6 h
after induction and reaches a maximum level at 16±24 h. In this
study, the expression of ICAM-1 and VCAM-1 started to increase at
1 h and reached a peak at 16 h and their presence was evident at 24 h
(Pober and Cotran, 1990; Swerlick et al, 1992a). In this study, the
induction of E-selectin reached a peak at 4 h and then disappeared
quickly. Thus stimulation of HDMEC by conditioned media causes
an increase in the expression of endothelial cell adhesion molecules,
similar to stimulation with IL-1a or TNF-a. By using blocking
antibodies and attempting to measure the TNF-a levels in
conditioned media, we were able to show that the action of anti-
FceRIa antibody could at least in part, be attributed to the
production of TNF-a from mast cells and endothelial activation.
The expression of endothelial cell adhesion molecules (ICAM-1,
VCAM-1, E-selectin) are induced by bacterial endotoxin or
various cytokines (e.g., IL-1, IL-4, TNF-a, IL-13, histamine,
IFN-g). Thus, cell adhesion molecule expression can be induced by
certain factors such as IL-1, IL-4, or IL-13 from mast cells,
mononuclear cells, T lymphocytes, or the endothelial cell itself. In
addition, previous studies have shown that some circulating
antibodies can activate endothelial cells directly. Anti-endothelial
cell antibody can play a pathogenic role in scleroderma by
activating endothelial cells, in part due to the autocrine or paracrine
actions of IL-1 (Carvalho et al, 1996). Also, anti-endothelial cell
antibody can induce the expression of ICAM-1 on HDMEC in
BehcËet's disease (Lee et al, 1999). We suspect that the mediators
(histamine, LTD4, TNF-a, etc.) released from mast cells challenged
with sera of CU patients stimulate the endothelial cells during
coculture, and then endothelial cells may produce some cytokines.
Therefore, we designed a coculture supernatant study to examine
whether the anti-human IgG antibody in some of the sera classi®ed
as having a FceRI antibody might induce the expression of
endothelial cell adhesion molecules directly and to determine
whether coculture supernatants may have synergistic effects for the
expression of cell adhesion molecules. Our results showing no
synergistic effects suggests that anti-FceRIa antibody did not affect
the activation of endothelial cells directly and there are no additive
autocrine effects of endothelial cell cytokines produced by mast cell
activation.
Although the exact pathogenesis of CU is still unknown, it seems
that anti-FceRIa antibody plays a part in CU by activating mast
cells, TNF-a production, and endothelial cells and enhancing
adhesion molecule expression. Activation of endothelial cells will
facilitate leukocyte traf®c and thus initiate in¯ammation.
Circulating functional autoantibodies to the high-af®nity IgE
receptor (FceRI) as well as to IgE have been found in approxim-
ately one-third of patients with chronic idiopathic urticaria and
anti-human IgG autoantibody might have picked up IgE/anti-IgE
Figure 4. Time course of the induction of the expression of
endothelial adhesion molecules in response to culture super-
natants from anti-FceRIa antibody-positive sera-treated mast
cells. Following the pretreatment of culture supernatants from anti-
FceRIa antibody-positive sera-treated mast cells, the expression of
endothelial adhesion molecules was assessed by ELISA. after 1, 4, 16, and
24 h of incubation. Results are presented as mean 6 SD. All data points
were performed in triplicate. Results shown are representative of three
separate experiments and two different sera. *p < 0.05 vs untreated
HDMEC.
Figure 5. Effect of anti-TNF-a monoclonal antibody on the
expression of endothelial adhesion molecules after pretreatment
with culture supernatants from anti-FceRIa antibody-positive
sera-treated mast cells. HDMEC were treated at 16 h for ICAM-1
and VCAM-1 expression or at 4 h for E-selectin expression with media
only (unstimulated) and culture supernatants (MC Sup), in the presence
or absence of blocking antibodies to TNF-a. The expression of
endothelial adhesion molecules was assessed by ELISA. Results are
presented as mean 6 SD. All data points were performed in triplicate.
Results shown are representative of three separate experiments and two
different sera. *p < 0.05 vs MC Sup.
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complexes (as well as anti-FceRI antibody) bound to the soluble
a-subunit on the ELISA. In this study, we used sera that had not
been preincubated with anti-IgE antibody or had not been treated
with heat. Thus, some of the sera classi®ed as having anti-FceRI
antibody might have had anti-IgE antibody. The possibility of
histamine-releasing activity by some sera containing anti-IgE
antibody cannot be excluded at the present time. Additional
studies using a puri®ed anti-FceRI antibody will be needed.
This work was supported by the ®nancial support of the Korea Research Foundation
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